2014
KRAS mutation testing in clinical practice
Perincheri S, Hui P. KRAS mutation testing in clinical practice. Expert Review Of Molecular Diagnostics 2014, 15: 375-384. PMID: 25487540, DOI: 10.1586/14737159.2015.986102.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKRAS mutation testingKRAS mutationsMetastatic colorectal carcinomaLung cancer patientsMutations of KRASCommon human malignanciesMutation testingCombinatorial therapeutic strategiesCancer patientsColorectal carcinomaThyroid cancerClinical aggressivenessClinical OncologyTherapeutic strategiesClinical practiceMolecular testingCytological specimensHuman malignanciesPrecision medicinePatientsCancerEssential biomarkersDownstream effectorsCurrent practiceMutations
2005
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 6373-6379. PMID: 16174717, DOI: 10.1210/jc.2005-0987.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerBRAF mutation statusBRAF mutationsClinicopathological predictorsRisk stratificationClinicopathological outcomesThyroid cancerPTC subtypesMutation statusTumor stage III/IVStage I/II diseaseMultivariate analysisTumor BRAF mutation statusStage III/IVInitial tumor characteristicsLymph node metastasisPoor clinicopathological outcomesInitial surgeryRecurrent diseaseClinical courseIndependent predictorsNode metastasisClinicopathological characteristicsSubsequent recurrenceTreatment failure